Cure8 trial brief
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side effects, and long-term management trade-offs.
Adults with ulcerative colitis in deep remission; IBD clinicians considering de-escalation; researchers studying remission and biomarkers.
This is a prospective, partially randomized, patient-preference interventional trial recruiting at the University of Chicago. Eligible adults in deep remission (endoscopic and histologic quiescence) may choose to de-escalate therapy or be randomized if they have no strong preference.
De-escalation is defined as stepping down from biologic or small-molecule therapy to oral aminosalicylate therapy or complete discontinuation; patients on immunomodulators or aminosalicylates would stop therapy.
Participants will be followed with clinical assessments, fecal calprotectin and CRP, intestinal ultrasound, and endoscopy/biopsies; primary outcomes focus on sustained biochemical, sonographic, clinical, and endoscopic remission at 12 months.
The design prioritizes real-world applicability by allowing patient preference while preserving randomization for undecided participants.
This is a recruiting interventional trial at a single tertiary center with a partially randomized, patient-preference design. The record describes planned methods and outcomes but does not report results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
